Team-based Care for Advanced Heart Failure

Heart Failure Clinics

Volumn 11, Issue 3, 2015, Pages 467-477

  Wever Pinzon, Omar ^a   Drakos, Stavros G ^b   Fang, James C ^b  

^a Department of Medicine   (United States)

^b UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

Author keywords

Heart failure; LVAD; Multidisciplinary team

Indexed keywords

ADVANCED HEART FAILURE; ADVERSE OUTCOME; BLEEDING TENDENCY; BRAIN HEMORRHAGE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; DEVICE INFECTION; FUNCTIONAL STATUS; GASTROINTESTINAL HEMORRHAGE; HEALTH CARE; HEALTH CARE COST; HEALTH PROGRAM; HEART DEATH; HEART FAILURE; HOSPITALIZATION; HUMAN; INTERPERSONAL COMMUNICATION; LEFT VENTRICULAR ASSIST DEVICE; LENGTH OF STAY; LONG TERM CARE; MANAGED CARE; MEDICAL STAFF; MORBIDITY; OUTCOME ASSESSMENT; PALLIATIVE THERAPY; PATIENT CARE; PATIENT MONITORING; PATIENT PREFERENCE; PATIENT REFERRAL; PATIENT SATISFACTION; PRACTICE GUIDELINE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TEAM BASED CARE; THROMBOSIS; TIME TO TREATMENT; CLINICAL TRIAL (TOPIC); ECONOMICS; HEART ASSIST DEVICE; ORGANIZATION AND MANAGEMENT; PROCEDURES; UNITED STATES;

CLINICAL TRIALS AS TOPIC; HEART FAILURE; HEART-ASSIST DEVICES; HUMANS; PATIENT CARE TEAM; PATIENT-CENTERED CARE; UNITED STATES;

EID: 84937430326     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2015.03.009     Document Type: Review

References (41)

1. Go A.S., Mozaffarian D., Roger V.L., et al. Heart disease and stroke statistics-2014 update: a report from the American Heart Association. Circulation 2014, 129(3):e28-e292.
2. Nohria A., Lewis E., Stevenson L.W. Medical management of advanced heart failure. JAMA 2002, 287(5):628-640.
3. Adams K.F., Zannad F. Clinical definition and epidemiology of advanced heart failure. Am Heart J 1998, 135(6 Pt 2 Su):S204-S215.
4. Yancy C.W., Jessup M., Bozkurt B., et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013, 128(16):e240-e327.
5. Metra M., Ponikowski P., Dickstein K., et al. Advanced chronic heart failure: a position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2007, 9(6-7):684-694.
6. Kirklin J.K., Naftel D.C., Pagani F.D., et al. Sixth INTERMACS annual report: a 10,000-patient database. JHeart Lung Transpl 2014, 33(6):555-564.
7. Unroe K.T., Greiner M.A., Hernandez A.F., et al. Resource use in the last 6 months of life among Medicare beneficiaries with heart failure, 2000-2007. Arch Intern Med 2011, 171(3):196-203.
8. Long E.F., Swain G.W., Mangi A.A. Comparative survival and cost-effectiveness of advanced therapies for end-stage heart failure. Circ Heart Fail 2014, 7(3):470-478.
9. McAlister F.A., Stewart S., Ferrua S., et al. Multidisciplinary strategies for the management of heart failure patients at high risk for admission: a systematic review of randomized trials. JAm Coll Cardiol 2004, 44(4):810-819.
10. Feltner C., Jones C.D., Cene C.W., et al. Transitional care interventions to prevent readmissions for persons with heart failure: a systematic review and meta-analysis. Ann Intern Med 2014, 160(11):774-784.
11. White S.M., Hill A. Aheart failure initiative to reduce the length of stay and readmission rates. Prof Case Manag 2014, 19(6):276-284.
12. Kasper E.K., Gerstenblith G., Hefter G., et al. Arandomized trial of the efficacy of multidisciplinary care in heart failure outpatients at high risk of hospital readmission. JAm Coll Cardiol 2002, 39(3):471-480.
13. Rich M.W., Gray D.B., Beckham V., et al. Effect of a multidisciplinary intervention on medication compliance in elderly patients with congestive heart failure. Am J Med 1996, 101(3):270-276.
14. McDonald K., Ledwidge M., Cahill J., et al. Elimination of early rehospitalization in a randomized, controlled trial of multidisciplinary care in a high-risk, elderly heart failure population: the potential contributions of specialist care, clinical stability and optimal angiotensin-converting enzyme inhibitor dose at discharge. Eur J Heart Fail 2001, 3(2):209-215.
15. Richardson L.G. Psychosocial issues in patients with congestive heart failure. Prog Cardiovasc Nurs 2003, 18(1):19-27.
16. Krumholz H.M., Butler J., Miller J., et al. Prognostic importance of emotional support for elderly patients hospitalized with heart failure. Circulation 1998, 97(10):958-964.
17. Jaarsma T., Beattie J.M., Ryder M., et al. Palliative care in heart failure: a position statement from the palliative care workshop of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2009, 11(5):433-443.
18. Park S.J., Tector A., Piccioni W., et al. Left ventricular assist devices as destination therapy: a new look at survival. JThorac Cardiovasc Surg 2005, 129(1):9-17.
19. Long J.W., Healy A.H., Rasmusson B.Y., et al. Improving outcomes with long-term "destination" therapy using left ventricular assist devices. JThorac Cardiovasc Surg 2008, 135(6):1353-1360. [discussion: 1360-1].
20. Holdy K., Dembitsky W., Eaton L.L., et al. Nutrition assessment and management of left ventricular assist device patients. JHeart Lung Transpl 2005, 24(10):1690-1696.
21. Alsara O., Reeves R.K., Pyfferoen M.D., et al. Inpatient rehabilitation outcomes for patients receiving left ventricular assist device. Am J Phys Med Rehabil 2014, 93(10):860-868.
22. English M.L., Speed J. Effectiveness of acute inpatient rehabilitation after left ventricular assist device placement. Am J Phys Med Rehabil 2013, 92(7):621-626.
23. Moreno S.G., Novielli N., Cooper N.J. Cost-effectiveness of the implantable HeartMate II left ventricular assist device for patients awaiting heart transplantation. JHeart Lung Transplant 2012, 31(5):450-458.
24. Smedira N.G., Hoercher K.J., Lima B., et al. Unplanned hospital readmissions after HeartMate II implantation: frequency, risk factors, and impact on resource use and survival. JACC Heart Fail 2013, 1(1):31-39.
25. Murray M.A., Osaki S., Edwards N.M., et al. Multidisciplinary approach decreases length of stay and reduces cost for ventricular assist device therapy. Interact Cardiovasc Thorac Surg 2009, 8(1):84-88.
26. Modica M., Ferratini M., Torri A., et al. Quality of life and emotional distress early after left ventricular assist device implant: a mixed-method study. Artif Organs 2015, 39(3):220-227.
27. Karapolat H., Engin C., Eroglu M., et al. Efficacy of the cardiac rehabilitation program in patients with end-stage heart failure, heart transplant patients, and left ventricular assist device recipients. Transplant Proc 2013, 45(9):3381-3385.
28. Starling R.C., Naka Y., Boyle A.J., et al. Results of the post-U.S. Food and Drug Administration-approval study with a continuous flow left ventricular assist device as a bridge to heart transplantation: a prospective study using the INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support). JAm Coll Cardiol 2011, 57(19):1890-1898.
29. Jorde U.P., Kushwaha S.S., Tatooles A.J., et al. Results of the destination therapy post-food and drug administration approval study with a continuous flow left ventricular assist device: a prospective study using the INTERMACS registry (Interagency Registry for Mechanically Assisted Circulatory Support). JAm Coll Cardiol 2014, 63(17):1751-1757.
30. Crow S., Chen D., Milano C., et al. Acquired von Willebrand syndrome in continuous-flow ventricular assist device recipients. Ann Thorac Surg 2010, 90(4):1263-1269. [discussion: 1269].
31. Wever-Pinzon O., Selzman C.H., Drakos S.G., et al. Pulsatility and the risk of nonsurgical bleeding in patients supported with the continuous-flow left ventricular assist device HeartMate II. Circ Heart Fail 2013, 6(3):517-526.
32. Kushnir V.M., Sharma S., Ewald G.A., et al. Evaluation of GI bleeding after implantation of left ventricular assist device. Gastrointest Endosc 2012, 75(5):973-979.
33. Starling R.C., Moazami N., Silvestry S.C., et al. Unexpected abrupt increase in left ventricular assist device thrombosis. NEngl J Med 2014, 370(1):33-40.
34. Fried J., Levin A.P., Mody K.M., et al. Prior hematologic conditions carry a high morbidity and mortality in patients supported with continuous-flow left ventricular assist devices. JHeart Lung Transplant 2014, 33(11):1119-1125.
35. Willey J.Z., Demmer R.T., Takayama H., et al. Cerebrovascular disease in the era of left ventricular assist devices with continuous flow: risk factors, diagnosis, and treatment. JHeart Lung Transplant 2014, 33(9):878-887.
36. Wever-Pinzon O., Stehlik J., Kfoury A.G., et al. Ventricular assist devices: pharmacological aspects of a mechanical therapy. Pharmacol Ther 2012, 134(2):189-199.
37. Taghavi S., Beyer C., Vora H., et al. Non-cardiac Surgery in patients on mechanical circulatory support. ASAIO J 2014, 60(6):670-674.
38. Gogas B.D., Parissis J.T., Filippatos G.S., et al. Severe anaemia and subcapital femur fracture in a patient with Left Ventricular Assist Device Heart Mate II: the cardiologist's management of this rare patient. Eur J Heart Fail 2009, 11(8):806-808.
39. Brush S., Budge D., Alharethi R., et al. End-of-life decision making and implementation in recipients of a destination left ventricular assist device. JHeart Lung Transplant 2010, 29(12):1337-1341.
40. Schaefer K.G., Griffin L., Smith C., et al. An interdisciplinary checklist for left ventricular assist device deactivation. JPalliat Med 2014, 17(1):4-5.
41. Gafford E.F., Luckhardt A.J., Swetz K.M. Deactivation of a left ventricular assist device at the end of life #269. JPalliat Med 2013, 16(8):980-982.